Methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia in haemodialysis patients by Cuervo Requena, Guillermo et al.
RESEARCH ARTICLE Open Access
Methicillin-resistant Staphylococcus aureus
(MRSA) catheter-related bacteraemia in
haemodialysis patients
Guillermo Cuervo1*, Mariana Camoez2, Evelyn Shaw1, María Ángeles Dominguez2, Oriol Gasch3, Belén Padilla4,
Vicente Pintado5, Benito Almirante6, José Molina7, Francisco López-Medrano8, Enrique Ruiz de Gopegui9,
José A. Martinez10, Elena Bereciartua11, Fernando Rodriguez-Lopez12, Carlos Fernandez-Mazarrasa13,
Miguel Ángel Goenaga14, Natividad Benito15, Jesús Rodriguez-Baño16, Elena Espejo17, Miquel Pujol1 and On behalf
of the REIPI/GEIH study group
Abstract
Background: The aim of the study was to determine clinical and microbiological differences between patients
with methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia (CRB) undergoing or not
undergoing haemodialysis, and to compare outcomes.
Methods: Prospective multicentre study conducted at 21 Spanish hospitals of patients with MRSA bacteraemia
diagnosed between June 2008 and December 2009. Patients with MRSA-CRB were selected. Data of patients
on haemodialysis (HD-CRB) and those not on haemodialysis (non-HD-CRB) were compared.
Results: Among 579 episodes of MRSA bacteraemia, 218 (37.7 %) were CRB. Thirty-four (15.6 %) were HD-CRB and 184
(84.4 %) non-HD-CRB. All HD-CRB patients acquired the infection at dialysis centres, while in 85.3 % of the non-HD-CRB
group the infection was nosocomial (p < .001). There were no differences in age, gender or severity of bacteraemia (Pitt
score); comorbidities (Charlson score≥ 4) were higher in the HD-CRB group than in the non-HD-CRB group (73.5 % vs.
46.2 %, p = .003). Although there were no differences in VAN-MIC ≥1.5 mg/L according to microdilution, using
the E-test a higher rate of VAN-MIC ≥1.5 mg/L was observed in HD-CRB than in non-HD-CRB patients (63.3 %
vs. 44.1 %, p = .051). Vancomycin was more frequently administered in the HD-CRB group than in the non-HD-CRB
group (82.3 % vs. 42.4 %, p = <.001) and therefore the appropriate empirical therapy was significantly higher in HD-CRB
group (91.2 % vs. 73.9 %, p = .029). There were no differences with regard to catheter removal (79.4 % vs.
84.2 %, p = .555, respectively). No significant differences in mortality rate were observed between both groups
(Overall mortality: 11.8 % vs. 27.2 %, p = .081, respectively), but there was a trend towards a higher recurrence
rate in HD-CRB group (8.8 % vs. 2.2 %, p = .076).
Conclusions: In our multicentre study, ambulatory patients in chronic haemodialysis represented a significant
proportion of cases of MRSA catheter-related bacteraemia. Although haemodialysis patients with MRSA
catheter-related bacteraemia had significantly more comorbidities and higher proportion of strains with
reduced vancomycin susceptibility than non-haemodialysis patients, overall mortality between both groups
was similar.
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Background
Methicillin-resistant Staphylococcus aureus (MRSA)
bloodstream infection (BSI) has been a cause of major
concern in healthcare systems all over the world, due
to its high incidence rates and undesirable related
outcomes [1–3]. Most series have found that the vascular
catheter is the most frequent source of MRSA-BSI [2, 3].
Chronic haemodialysis patients, especially those dia-
lysed through a venous catheter [4–6] are at a par-
ticularly high risk of this infection, with a rate more
than 100 times higher than non-dialysis patients [4, 7].
Among haemodialysis patients with staphylococcal in-
fections, those with MRSA infections have significantly
longer hospitalizations, with higher costs, and are more
likely to die within three months than those with
methicillin-susceptible Staphylococcus aureus (MSSA)
infections [8].
Patients with MRSA infections often receive antibiotic
treatment with glycopeptides [9]. Some reports have
raised concerns about the observation of higher vanco-
mycin MICs in isolates of patients with MRSA bacter-
aemia who had received vancomycin within the last
30 days [10, 11], and other authors have also docu-
mented a significant risk for treatment failure and a
higher mortality with increasing vancomycin MIC, even
if MICs are in the susceptible range [12, 13]. Similar
findings were reported specifically in patients undergo-
ing haemodialysis, in whom a higher mortality and a
longer mean hospital length of stay were also observed,
with an ensuing increase in hospital costs [14].
Current information on this topic is still scarce in
Europe, particularly in patients receiving haemodialy-
sis who develop catheter-related MRSA bacteraemia
(HD-CRB). We aimed to analyse this issue in a large
multicentre prospective cohort of patients with MRSA
bacteraemia from Spain. Our objective was to com-
pare the clinical presentation, microbiological charac-
teristics and outcomes in this group of patients and
in patients with MRSA catheter-related bacteraemia
who were not receiving HD (non-HD-CRB).
Methods
Study period and patients
This was post-hoc analysis of a prospective multicentre
study of all consecutive episodes of MRSA bacteraemia
in hospitalized adult patients occurring from June 2008
to December 2009 at 21 Spanish hospitals. The following
information was collected from medical records using a
standardized protocol: demographic characteristics, co-
morbidities, clinical features, antibiotic therapy, and out-
comes. Patients with catheter-related bacteraemia (CRB)
were selected for the study, and those undergoing
haemodialysis (HD-CRB) were compared with those
who were not (non-HD-CRB).
Definitions
MRSA bacteraemia was defined as the presence of at least
one positive blood culture for MRSA in a patient with
clinical signs and symptoms of sepsis [15]. Vascular
catheter-related bacteraemia was diagnosed using clinical
and microbiological criteria defined by the guidelines of
the Infectious Diseases Society of America [16]. It was
considered when MRSA grew from at least one percutan-
eous blood sample culture and from a culture of the cath-
eter tip, or when it grew in two blood samples for culture
(one from a catheter hub and the other from a peripheral
vein) that met criteria for quantitative blood cultures or
differential time to positivity in a patient with accompany-
ing clinical signs of sepsis and no other apparent source of
infection. Complicated bacteraemia was defined as those
episodes with positive follow-up blood cultures performed
at 2–4 days after the beginning of adequate therapy and/
or with evidence of metastatic infection or endocarditis
[17]. Comorbidity was measured by the Charlson score, as
described elsewhere [18]. Patients were classified into
three categories on the McCabe and Jackson scale
[19] according to their prognosis of survival before
the MRSA bacteraemia: rapidly fatal (death expected
within the following year), ultimately fatal (death ex-
pected within a period of 1 to 5 years), and non fatal
(life expectancy of > 5 years). Severity of sepsis in the
acute condition was assessed by the Pitt score [20].
Three acquisition categories were considered according to
the Friedman criteria [21]: nosocomial, healthcare-related,
and community-acquired bacteraemia. However, since all
cases had healthcare exposure (i.e., dialysis) prior to cul-
ture, no community-associated cases were included. Dis-
tant extension was diagnosed in the presence of at least
one distant infection secondary to blood spread seeding.
The empirical antibiotic was defined as the antibiotic ad-
ministered in the first 48 h after a positive blood culture
was drawn, and it was considered appropriate if the strain
was susceptible to at least one of the antibiotics adminis-
tered according to the current CLSI breakpoints [22]. All
patients were followed up to 4 weeks after completion of
antibiotic treatment whether they were hospitalized or
not. Recurrence within this period of time was defined as
the isolation of MRSA in blood cultures after documented
negative blood cultures or a newly diagnosed metastatic
focus of the bacteremic past infection. Overall mortality
was defined as death from any cause occurring in the
30 days and early mortality (EM) was defined for patients
who died within the first two days after the onset of
MRSA bacteraemia.
Susceptibility testing and molecular epidemiology of
MRSA isolates
MRSA strains were identified in each hospital, where
preliminary susceptibility tests were performed. Isolates
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were then sent to a central reference laboratory. All S.
aureus were identified by latex agglutination (Pastorex
Staph-plus, Bio-Rad Laboratories, Madrid, Spain) and
DNase production (DNasE-test Agar, BioMérieux, Marcy
l’Etoile, France). Antimicrobial susceptibility was tested
by the disc diffusion method according to the CLSI
guidelines [22]. MICs were determined by the microdilu-
tion method in accordance with CLSI criteria by using
commercial panels (ESTEN 2009, SensititreTM, Izasa,
Barcelona, Spain) read visually. Vancomycin E-test
(BioMérieux) MICs were determined using a 0.5
McFarland inoculum streaked evenly with a swab onto
Mueller-Hinton agar plates [23]. PFGE was performed
after SmaI restriction of chromosomal DNA [24]. Re-
striction patterns were interpreted in accordance with
criteria published elsewhere [25]. Representative isolates of
each PFGE type and subtype were studied to determine
the Multilocus Sequence Type (MLST) [26] and the
Staphylococcal Chromosome Cassette mec (SCCmec) types
[27]. MLSTs and SCCmec types were further inferred for
all the strains. The agr polymorphism and the presence of
genes encoding class S (lukS-PV) and class F (lukF-PV)
proteins for Panton–Valentine Leukocidin (PVL) were
studied by PCR in all the isolates, following the method-
ology described elsewhere [28, 29].
Statistical analysis
Continuous variables were compared using the Student’s
t-test or the Mann–Whitney U-test as appropriate.
Categorical data were compared using Fisher’s exact
or Chi-squared tests. Analyses were performed using
SPSS v15 (SPSS Inc., Chicago, IL, USA).
Ethical considerations
This observational study was conducted in accordance
with the Declaration of Helsinki and was approved by
the Spanish Network for Research in Infectious Dis-
eases (REIPI) and by the Institutional Review Board
at each participating centre: H. Arnau de Vilanova,
Lleida; H. Universitari de Bellvitge, Barcelona; H. de
Burgos, Burgos; H. Clìnic, Barcelona; H. Universitario
12 de Octubre, Madrid; H. de Cruces, Barakaldo; H.
de Donostia, Donostia; H. General Universitario Gregorio
Marañón, Madrid; H. Universitari Joan XXIII, Tarragona;
H. Universitari del Mar, Barcelona; H. Universitario
Marques de Valdecilla, Santander; H. Universitari
Mutua de Terrassa, Terrassa; H. del Parc Taulí, Sabadell;
H. Universitario Ramon y Cajal, Madrid; H. Universitario
Reina Sofía, Córdoba; H. San Pedro de la Rioja, Logroño;
H. de la Santa Creu i Sant Pau, Barcelona; H. Universitari
Son Espases, Palma de Mallorca; H. Universitario Virgen
Macarena, Sevilla; H. Universitario Virgen del Rocío,
Sevilla; H. Universitari Vall d’Hebrón, Barcelona. To
protect personal privacy, identifying information of
each patient in the electronic database was encrypted.
Informed consent was waived by the Clinical Research
Ethics Committee because no intervention was in-




From a total of 579 episodes of MRSA bacteraemia, 218
(37.7 %) were catheter-related (Fig. 1): 34 (15.6 %) oc-
curred in the HD-CRB group and 184 (84.4 %) in the
non-HD-CRB group. The clinical and microbiological
characteristics of patients are shown in Table 1. The
comparison between the groups did not find significant
differences in gender or age distribution. All HD-CRB
patients acquired the infection at dialysis centres
(chronic ambulatory haemodialysis), while the acquisi-
tion in non-HD-CRB patients was nosocomial in 85.3 %
of cases (p < .001). Comorbidities measured by the
Charlson score were higher in the HD-CRB group
(Charlson ≥4: n = 25, 73.5 % vs. n = 85, 46.2 %, p = .003)
while the severity of the underlying disease according
to the McCabe scale was lower in this group (McCabe ≥2:
n = 13, 38.2 % vs. n = 97, 52.7 %, p = .120). No differences
Fig. 1 Flow chart of patients included in analysis
Cuervo et al. BMC Infectious Diseases  (2015) 15:484 Page 3 of 7
were observed between groups in the severity of bacter-
aemia measured by the Pitt score.
Microbiologic studies
A dominant PFGE genotype (pulse-type 2) was found
in both groups (Table 1), with all isolates belonging
to Clonal Complex (CC) 5 (ST125 and ST146). They
carried a SCCmec element type IV and agr type 2.
PVL was positive in only two isolates in the non-HD-
CRB group, both belonging to the USA300 clone. No
isolates had vancomycin MIC ≥1.5 mg/L tested with
the broth microdilution method in the HD-CRB
group, compared with seven isolates (5 %) in the
non-HD-CRB group (p = .60). However, when MIC
was assessed by the E-test, 19 patients (63.3 %) in the
HD-CRB group had vancomycin MIC ≥1.5 mg/L, and
78 (44.1 %) in the non-HD-CRB (p = .051).
Treatment and outcomes
The treatment and clinical outcomes are detailed in
Table 2. Empirical therapy was considered appropri-
ate in 31 patients (91.2 %) in the HD-CRB group vs.
118 (64.1 %) in the non-HD-CRB group (p = .001).
Vancomycin was the most frequent empirical therapy
in the HD-CRB group, in which 28 patients received
vancomycin treatment (82.4 %) versus 78 patients
(42.4 %) in the non-HD-CRB group (p = <.001).
There were no significant differences between groups
in the number of catheters removed during the epi-
sode (n = 27, 79.4 % vs. n = 155, 84.2 %, p = .555). Al-
though no significant differences in outcomes were
observed, there was a trend towards recurrent bacter-
aemia in the HD-CRB group (3/34, 8.8 % vs. n = 4/
184, 2.2 %, p = .076).
Discussion
In this multicentre study of a large Spanish cohort in-
cluding a high number of patients with MRSA catheter-
related bacteraemia, patients receiving haemodialysis
did not present worse outcomes than the other group
of patients with MRSA catheter-related bacteraemia.
These findings challenge the results of previous reports
which suggested that patients receiving HD are more
prone to complications and poor prognosis [30, 31].
It is known that HD patients are frequently and recur-
rently colonized by MRSA [32, 33]. In fact, this patho-
logical condition is a well known risk factor for MRSA
bacteraemia [4, 34]. This is a matter of concern, as the
size of the dialysis population is increasing worldwide
Table 1 Clinical and microbiological characteristics of patients
by group
HD-CRB
n = 34 (100 %)
Non-HD-CRB
n = 184 (100 %)
p
Male Sex 23 (67.6) 113 (61.4) .491
Age > 70 y 16 (47.1) 92 (50) .753
Acquisition
Health-care 34 (100) 27 (14.7) <.001
Nosocomial 0 157 (85.3) <.001
Charlson score > 4 25 (73.5) 85 (46.2) .003
McCabe scale > 2 13 (38.2) 97 (52.7) .120
Pitt score > 3 6 (17.6) 55 (29.9) .144
Microbiology
agr typea I 3 (10) 44 (24.9) .082
II 27 (90) 132 (74.6) .354
PFGE typea 2 25 (83.3) 107 (60.5) .091
4 2 (6.7) 18 (10.2) .688
Other 3 (10) 52(29.3) .046
Clonal Complexb
5 28 (93.3) 128 (74.4) .128
8 0 14 (8.1) .199
22 2 (6.7) 17 (9.9) .759
Other 0 13 (7.6) .774
PVLa 0 2 (1.1) 1
Microdilution Vancomycin
MICa > = 1.5 mg/L
0 (4.9) .363
E-test Vancomycin
MICa > = 1.5 mg/L
19 (63.3) 78 (44.1) .051
aData available in 207 patients
bData available in 202 patients. Within Clonal Complex 5, 124 isolates
belonged to the ST125 clone (HD-CRB: 25/83.3 % vs. Non-HD-CRB: 99/57.6 %;
p = .013) whereas 9 isolates belonged to the ST146 clone (HD-CRB: 2/6.7 % vs.
Non-HD-CRB: 7/4 %; p = .875)
Abbreviations: HD-CRB Haemodialysis catheter-related bacteraemia, Non-HD-
CRB Non-haemodialysis catheter-related bacteraemia, agr Accessory gene regu-
lator, PFGE Pulsed field gel electrophoresis, PVL Panton Valentine Leukocidin, MIC
Minimum inhibitory concentration
Table 2 Treatments and clinical outcomes of patients by group
HD-CRB
n = 34 (100 %)
Non-HD-CRB
n = 184 (100 %)
p
Treatment (within 48 h)
Catheter removal 27 (79.4) 155 (84.2) .555
Vancomycin therapy 28 (82.3) 78 (42.4) <.001
Appropriate ATB therapya 31 (91.2) 118 (64.1) .002
Outcome
Persistent bacteraemia 3d 5 (14.7) 37 (20.1) .463
Persistent bacteraemia 7d 2 (5.9) 26 (14.1) .533
Complicated bacteraemia 11 (32.4) 89 (48.4) .095
Distant secondary focus 5 (15.2) 38 (20.7) .465
Endocarditis 0 10 (5.4) .368
Recurrence 3 (8.8) 4 (2.2) .076
Early mortality (48 h) 0 7 (3.8) .599
Overall mortality (30d) 4 (11.8) 49 (27.2) .081
aATB therapy: Antibiotic therapy
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[35], as well as the proportion of HD patients using a
catheter [36].
In our cohort of 579 MRSA patients, 218 (37.7 %)
had catheter-related bacteraemia, a rate similar to
other reports [37]. Patients on HD through a catheter
had a greater burden of comorbidities as measured by
Charlson score, a frequent finding in these patients [38].
Regarding vancomycin susceptibility tests, our findings
reproduce the highly variable and method-dependent
results already reported by some authors [39, 40]. None
of our HD-CRB patients had high MICs according to
microdilution, but the E-test method identified high
MICs in 19 of them. In spite of these E-test results,
however, our HD patients did not have poorer out-
comes, in agreement with other reports [14, 41]. In
other words, the MIC measured by E-test did not im-
prove the predictive ability of the microdilution in our
cohort, which challenges us about its accuracy as a
prognostic reference method. Vancomycin was the
most frequently prescribed empirical therapy in our
HD patients; its administration certainly is a common
practice in this population [9]. The high presumption
of MRSA in HD patients with a suspected infection
may explain the choice of a more appropriate anti-
biotic therapy for this group both in our cohort and
in others [42].
Although no significant differences in outcomes be-
tween groups were observed, HD patients had a ten-
dency towards a higher recurrence rate, in agreement
with previous research [43] but not a higher frequency
of endocarditis [5]. Taken together, patients with MRSA
catheter-related bacteraemia in our cohort had lower
early and overall mortality rates (3.2 % and 24 % re-
spectively) compared with studies which analysed
MRSA bacteraemia of all sources [44]. In fact, patients
with catheter-related bacteraemia represent a particular
group in which the main therapeutic strategy is cath-
eter removal; this was achieved within 48 h in 80 % of
our patients. Furthermore, some authors have sug-
gested that, rather than vancomycin MIC, the anatom-
ical site of infection may be the best predictor of
therapy success [42]. Finally, our HD patients exhib-
ited a trend towards lower early and total mortality
compared with the other group in which there was
significantly more inappropriate initial treatment, a
well known predictor of mortality [45]. In agreement
with our findings, some recent reports on Staphylo-
coccus aureus bacteraemia (both MSSA and MRSA)
found lower 30 and 90 days case fatality rates in pa-
tients with end stage renal disease, irrespective of the
type of replacement therapy received [46].
Our study has some limitations. First, it included a
relatively low number of HD patients with CRB, and
its multicentre nature may have introduced some
differences between centres regarding the clinical
management. However, to our knowledge, it is the
first study to address this specific population group
within all patients with MRSA bacteraemia. On the
other hand, isolates were frozen prior to MIC testing,
which potentially could have underestimated MIC lec-
ture in both groups [47].
Conclusion
In our multicentre study, ambulatory patients in chronic
haemodialysis represented a significant proportion of
cases of MRSA catheter-related bacteraemia. Although
haemodialysis patients had significantly more comorbidi-
ties and higher proportion of strains with reduced
vancomycin susceptibility than non-haemodialysis pa-
tients, they do not have worse outcomes. In fact, the
higher frequency of appropriate empirical antimicrobial
therapy may explain the trend towards better outcomes
in this group, even though the sample size could prevent
its statistical confirmation.
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